Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Feb 2005

Bang Sookhee, Nagata Satoshi, Onda Masanori, Kreitman Robert J, Pastan Ira

Abstract excerpt

PURPOSE: RFB4 (dsFv)-PE38 (BL22) is a recombinant immunotoxin containing an anti-CD22 (Fv) fused to truncated Pseudomonas exotoxin A, which induces a high complete remission rate in patients with purine analogue-resistant hairy cell leukemia. HA22 is a mutant of BL22 with mutations in heavy-chain CDR3 resulting in increased cytotoxic activity. Our goal was to improve the activity of HA22. EXPERIMENTAL DESIGN:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Diphosphate Ribose
Share to Antigens, Differentiation, B-Lymphocyte

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Enterotoxins

Share to Exotoxins

Share to GPI-Linked Proteins

Share to Immunotoxins

Share to Inhibitory Concentration 50

Share to Lectins

Source

Identifiers

PMID: 15746059
DOI: 10.1158/1078-0432.CCR-04-1939

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.PMID 15746059Read ↗

Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.Semantic proximity Read ↗

Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.Semantic proximity Read ↗

Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.Semantic proximity Read ↗

Immunoconjugates in the management of hairy cell leukemia.Semantic proximity Read ↗

Immunotoxins with decreased immunogenicity and improved activity.Semantic proximity Read ↗

Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell LeukemiaSemantic proximity Read ↗

A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.Semantic proximity Read ↗

A Modified Form of Diphthamide Causes Immunotoxin Resistance in a Lymphoma Cell Line with a Deletion of the WDR85 GeneSemantic proximity Read ↗

A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity.Semantic proximity Read ↗

Immunoconjugates and new molecular targets in hairy cell leukemia.Semantic proximity Read ↗

Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancySemantic proximity Read ↗

Removal of B-cell epitopes for decreasing immunogenicity in recombinant immunotoxin against B-cell malignancies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.